Skip to main content
OpenTrials
Completed

NCT Number: NCT04713852

Predictive Value of SOFA and APACHE Scores for In-hospital Mortality in COVID-19 ICU Patients

The aim of this study is to evaluate the predictive value for in-hospital mortality of respectively the SOFA and Apache scores in a COVID-19 ICU cohort and to develop a new prediction model for COVID-19 patients admitted to the ICU from 13th of March 2020 until 17th of October 2020.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Jessa hospital

Hasselt, 3500, Belgium

About this study

The coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) emerged in December 2019 and has rapidly spread worldwide. The mortality of critical ill patients with COVID-19 has been reported variously as low as 11% and as high as 61%. The application of scoring systems can facilitate the effective evaluation by physicians to screen severe patients. At present, however, there are no specific scoring systems for the evaluation of COVID-19 patients. Scoring systems such as the Sequential Organ Failure Assessment (SOFA) score can help emergency or critical care physicians for prognosis and predicting mortality. The SOFA score described the condition of multiple organ dysfunction through several parameters, including oxygenation index, mean arterial pressure, Glasgow come scale, creatinine or urine volume, bilirubin, platelets for the respiratory, circulatory, neurological, renal, hepatogenic and coagulation systems respectively. The function of each organ system is scored from 0 to 4, and the individual SOFA scores are summed to a total score. Although SOFA was not initially designed to predict mortality, several studies reveal that SOFA could predict morbidity and mortality in severe ill patients.

Besides the SOFA score, the Acute Physiology and Chronic Health Evaluation (Apache II) scores was designed to measure the severity of disease of patients admitted to the ICU and to predict mortality. The Apache II score is calculated based on physiological measurements such as body temperature, mean arterial pressure, pH, heart and respiratory rate, Glasgow coma scale, oxygenation and blood parameters such as sodium, potassium, creatinine, hematocrit and white blood cell count. Recently, the Apache IV score is developed where additional parameters such as admission information, admission diagnosis and chronic health conditions were take into account.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • COVID-19 patients admitted to the ICU from 13th of March 2020 until 17th October 2020.

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. Mortality

    Time frame: Patients admitted from 13th march 2020 to 17th october 2020

    To predict the mortality based on the SOFA and Apache scores in critically ill ICU patients

Secondary outcomes

  1. Predictive value

    Time frame: Patients admitted from 13th march 2020 to 17th october 2020

    Predictive value of DNR code, gender, BMI, hypertension, Diabetes, age, P/F ratio, anticoagulation and Rockwood Clinical Frailty index

Sponsors and collaborators

Lead sponsor

Jessa Hospital

Other

Registry information

Official study title

Predictive Value of SOFA and APACHE Scores for In-hospital Mortality in COVID-19 ICU Patients: a Longitudinal Single-center Study

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jan 19, 2021
Registry last updated
Sep 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.